🇺🇸 SECHUTCHMED (China) LtdDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:08:29·⟳ 抓取 18:09:46 +1m17s·⚡ 决策 10-27 20:02:07 +1h52m·1.1 小时前
和黄医药宣布11月5日与花旗合办赛沃替尼NSCLC最新III期数据专家网络电话会，无新增临床或监管事实
SEC 6-K所附新闻稿本质是‘Save the Date’式投资者关系活动通知，讨论的SANOVO与SAFFRON III期数据均为ESMO 2026已公开内容；本臂近72小时内已就SANOVO阳性结果（10-26）和SAFFRON详细数据（10-26）各做过一次不做研判，本条没有任何新终点、监管行动、金额或指引，无预期差，不构成做多或做空催化
📄 原文HUTCHMED (China) Ltd↗ 原文
----- hcm-20261027x6k.htm ----- 6-K 1 hcm-20261027x6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wash…
不做 和黄医药（00013.HK）
无增量事实：6-K仅为11月5日赛沃替尼ESMO数据专家电话会的日程预告，SANOVO/SAFFRON数据均已公开并被研判消化，无预期差；不做多，会议性质也不构成做空催化
不做 和黄医药(ADR)（HCM.US）
同一发行人ADR，公告无新基本面且美股当前盘前不可成交；11月5日会议若有超预期表态再另行评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
和黄医药仅预告11月5日与花旗合办赛沃替尼NSCLC数据专家电话会，所涉SANOVO/SAFFRON阳性III期数据此前均已官方首发并经市场消化，属无新增事实的IR通知，不交易；可将11月5日会议作为未来潜在信息事件跟踪。
🔎 新鲜度:最早出现 2026-10-27 · 扩散 low · price-in 风险 high ↗
关键理由
- 无多空edge：公告不含新临床/监管/财务增量，核心数据已于8月底至10月26日充分公开
主要风险
- 11月5日电话会若出现超ESMO范围的积极监管或亚组表态可能引发短线行情，但那是未来事件，不应基于日程预告提前博弈
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
本公告未包含任何超出ESMO 2026已公布SANOVO/SAFFRON数据的新终点、监管受理或批准；无新利多支撑做多
检索:HUTCHMED savolitinib new data sNDA FDA approval November 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认不做多也不做空，仅把11月5日会议列为未来观察点
方向:无可对齐的交易级先例：事件本身不是临床读出/监管节点，而是IR活动预告，事件研究先例不适用
涨幅量级:不足以校准涨跌幅，因无增量基本面
形态:本臂内部近72小时已就同一药物的两批实际数据各研判一次，结论均为不做（数据已price-in/AZN materiality低）；日程通知的edge弱于实际数据公布
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 506 ms
{"result": "search_processed_events:agent query=`hutchmed hcm savolitinib nsclc phase iii data investor event november 5 | hutchmed savolitinib sanovo esmo 2026 expert webcast citigroup | 和黄医药 赛沃替尼 saffron sanovo 专家网络电话会`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.8/72 小时、4885 条本臂决策(完整)，返回 2 条候选。\n• 10-26 10:48 UT - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{
原文全文
展开原文 · 10,668 字
----- hcm-20261027x6k.htm -----
6-K
1
hcm-20261027x6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the
Month of October 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
⌧
Form 40-F
◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No.
Description
Exhibit 99.1
Press release relating to HUTCHMED
to host expert insights event on recent savolitinib clinical data in non-small cell lung cancer
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
HUTCHMED (CHINA) LIMITED
By:
/s/ Johnny Cheng
Name:
Johnny Cheng
Title:
Chief Financial Officer
Date: October 27, 2026
3
----- hcm-ex99d1.htm -----
EX-99.1
2
hcm-ex99d1.htm
EX-99.1
Exhibit 99.1
Press Release
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 2
7
, 2026:
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;
HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on
Thursday, November 5, 2026, at 4:30 pm HKT
/
8:30 am GMT / 3:30 am EST.
The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer (presently on leave of absence) and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.
The webcast will be conducted in Chinese (Putonghua) with simultaneous English interpretation.
Event and registration details will be available at www.hutch-med.com/event.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.
Savolitinib is marketed in China under the brand name ORPATHYS
®
for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. Savolitinib also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. Savolitinib in combination with TAGRISSO
®
is approved in China for patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO
®
. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) in August 2026.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
About SANOVO
SANOVO is a blinded, randomized, controlled Phase III trial in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. The study evaluates the efficacy and safety of savolitinib in combination with TAGRISSO
®
compared to TAGRISSO
®
alone, a standard-of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic NSCLC harbouring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO
®
80 mg once daily plus either savolitinib
or placebo at 300/200 mg twice daily (dosed based on body weight).
The primary endpoint of the trial is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate, duration of response, disease control rate, time to response and safety.
About SAFFRON
SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of savolitinib (300 mg twice daily) added to TAGRISSO
®
(80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO
®
. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.
Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib
would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of savolitinib
for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize savolitinib. In addition, as certain studies rely on the use of other drug products such as TAGRISSO
®
as combination therapeutics with savolitinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
Investor Enquiries
+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –
+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper
+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum
Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden
+44 20 7886 2500
Cavendish
Joint Broker
Geoff Nash / Nigel Birks
+44 20 7220 0500
Deutsche Numis
Joint Broker
Duncan Monteith / Ramin Naji
+44 20 7545 8000
6-K
1
hcm-20261027x6k.htm
6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the
Month of October 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
⌧
Form 40-F
◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No.
Description
Exhibit 99.1
Press release relating to HUTCHMED
to host expert insights event on recent savolitinib clinical data in non-small cell lung cancer
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
HUTCHMED (CHINA) LIMITED
By:
/s/ Johnny Cheng
Name:
Johnny Cheng
Title:
Chief Financial Officer
Date: October 27, 2026
3
----- hcm-ex99d1.htm -----
EX-99.1
2
hcm-ex99d1.htm
EX-99.1
Exhibit 99.1
Press Release
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 2
7
, 2026:
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;
HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on
Thursday, November 5, 2026, at 4:30 pm HKT
/
8:30 am GMT / 3:30 am EST.
The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer (presently on leave of absence) and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.
The webcast will be conducted in Chinese (Putonghua) with simultaneous English interpretation.
Event and registration details will be available at www.hutch-med.com/event.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.
Savolitinib is marketed in China under the brand name ORPATHYS
®
for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. Savolitinib also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. Savolitinib in combination with TAGRISSO
®
is approved in China for patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO
®
. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) in August 2026.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
About SANOVO
SANOVO is a blinded, randomized, controlled Phase III trial in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. The study evaluates the efficacy and safety of savolitinib in combination with TAGRISSO
®
compared to TAGRISSO
®
alone, a standard-of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic NSCLC harbouring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO
®
80 mg once daily plus either savolitinib
or placebo at 300/200 mg twice daily (dosed based on body weight).
The primary endpoint of the trial is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate, duration of response, disease control rate, time to response and safety.
About SAFFRON
SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of savolitinib (300 mg twice daily) added to TAGRISSO
®
(80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO
®
. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.
Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib
would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of savolitinib
for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize savolitinib. In addition, as certain studies rely on the use of other drug products such as TAGRISSO
®
as combination therapeutics with savolitinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
Investor Enquiries
+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –
+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper
+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum
Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden
+44 20 7886 2500
Cavendish
Joint Broker
Geoff Nash / Nigel Birks
+44 20 7220 0500
Deutsche Numis
Joint Broker
Duncan Monteith / Ramin Naji
+44 20 7545 8000
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ccdd5466d9· 2026-10-27 20:02 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前